We speculate that the higher risk of death in HCC patients with high plasma levels of sIL-6R and sgp130 at baseline and high plasma levels of sIL-6R alone early during SBRT might be attributed to decreased inhibition of IL-6:sIL-6R trans-signaling by sgp130. This evidence concerns the gene IL6 and hepatocellular carcinoma.